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ABSTRACT 
Proteins highly represented in milk such as α-lactalbumin and lactoferrin bind Oleic Acid (OA) to form 
complexes with selective anti-tumor activity. A protein present in milk, colostrum and blood, vitamin D 
binding protein is the precursor of a potent Macrophage Activating Factor (GcMAF) and in analogy with 
other OA-protein complexes, we proposed that OA-GcMAF could demonstrate a greater 
immunotherapeutic activity than that of GcMAF alone. We describe a preliminary experience treating 
patients with advanced cancers, often labelled as “incurable” with an integrative immunotherapy centred on 
OA-GcMAF. Patients with advanced cancer were treated at the Immuno Biotech Treatment Centre with 
OA-GcMAF-based integrative immunotherapy in combination with a very low carbohydrate, high protein 
diet, fermented milk products containing naturally produced GcMAF, vitamin D3 and low-dose 
acetylsalicylic acid. When the primary tumor or a metastasis could be measured by ultrasonographic 
techniques, we observed, on average, a decrease of tumor volume of approximately 25% in a week. We also 
observed a consistent increase in splenic blood flow that was interpreted in the context of generalised 
immune system activation and allowed to assess the degree of responsiveness of the individual patient. The 
results reported here are consistent with the results previously described in the experimental animal harbouring a 
human hepatocellular carcinoma as well as with the results reported for neoadjuvant chemotherapy. OA-protein 
complexes are bound to play a leading role in cancer therapy thanks to selectivity of antitumoral effects, absence 
of any side effects, safety and oral availability. We hypothesise that OA-GcMAF, combines the known anticancer 
effects OA-protein complexes with the well established immune stimulating effects of GcMAF. 
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1. INTRODUCTION 
It is well assessed that proteins highly represented in 
milk such as α-lactalbumin and lactoferrin can bind 
Oleic Acid (OA) to form complexes, which exhibit 
highly selective anti-tumor activity in vitro and in vivo 
(Fang et al., 2013). Recent observations seem to indicate 
that OA plays the key role in the tumoricidal action of 
these protein-OA complexes (Hoque et al., 2013). Study 
of the structural features of such tumoricidal protein-OA 
complexes demonstrated that all these complexes exhibit 
a common feature that is a tendency toward protein 
oligomerization. Since OA-induced oligomerization has 
been reported for other proteins as well, it was 
hypothesised that this phenomenon may be inherent to 
many proteins (Nemashkalova et al., 2013). 
It should be noticed that some of the milk proteins 
forming OA-protein tumoricidal complexes, such as 
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lactoferrins, are potent modulators of the immune 
system (Vogel, 2012), thus lending credit to the 
hypothesis that the immune system is involved in the 
anticancer effects of OA-protein complexes. 
In addition to lactoferrins, another immunogenic 
protein highly represented in milk, as well as in 
colostrum and blood, is the vitamin D binding protein. 
This is the precursor of a very potent macrophage 
activating factor that derives from its selective de-
glycosylation. Since vitamin D binding protein is also 
termed Gc-globulin, this macrophage activating factor is 
known as Gc-globulin-derived Macrophage Activating 
Factor (GcMAF) (for review on vitamin D binding 
protein and GcMAF, Ruggiero and Pacini, 2011). 
The potent immunotherapeutic effects of GcMAF in 
human tumors have been demonstrated since 2007 in a 
variety of cancers ranging from the most common breast 
and prostate cancers to the less frequent 
oligodendroglioma (Yamamoto et al., 2008a; 2008b; 
2008c; Inui et al., 2013; Thyer et al., 2013a; 2013b). 
Therefore, in analogy with other OA-protein complexes, 
we postulated that OA-GcMAF complexes could show an 
antitumor activity even greater than that of GcMAF alone. 
Since OA-protein complexes and GcMAF show no 
evidence of toxicity (Ho et al., 2012; Bradstreet et al., 
2012), these complexes were selected as part of an 
integrative immunotherapeutic approach to advanced 
cancers in the context of the so-called compassionate 
approach. In this study we describe the preliminary 
experiences of treating patients with advanced cancers, 
some of them considered as “incurable”, with an integrative 
immunotherapy centred on OA-GcMAF. 
2. PATIENTS AND METHODS 
At the Immuno Biotech Treatment Centre, patients 
with advanced late stage 4 cancer, are currently being 
treated with an OA-GcMAF-based integrative 
immunotherapy. OA-GcMAF is used in combination with 
a very low carbohydrate, high protein diet that is known to 
slow tumor growth and prevent cancer initiation (Ho et al., 
2011), fermented milk products containing naturally 
produced GcMAF, high vitamin D3 supplementation 
(Den Hollander et al., 2013) and low-dose acetylsalicylic 
acid (Thun et al., 2012). All of these approaches aim to 
strengthen and activate the immune system and can be 
considered complementary and not alternative to other 
anti-neoplastic therapeutic procedures that the patients 
may want to take into consideration. 
2.1. OA-GcMAF 
OA-GcMAF complexes were prepared “in-house” at 
immuno biotech with a proprietary procedure. Briefly, 
GcMAF was purified according to the procedure 
previously described (Yamamoto et al., 2008b). Vitamin 
D binding protein was isolated from purified human 
serum obtained from the American Red Cross, using 
either 25-hydroxyvitamin D3-sepharose high affinity 
chromatography or actin-agarose affinity 
chromatography. The bound material was eluted and 
then further processed by incubation with three 
immobilized enzymes as described (Bradstreet et al., 
2012). The resulting GcMAF was filter sterilized. The 
protein content and concentration was assayed using 
standard Bradford protein assay methods (Bradford, 
1976). Purity was assessed by SDS-PAGE and Western 
Blot analysis performed after each step of the preparation 
procedure; only one band of the expected molecular 
weight was visible (Smith et al., 2013). At the end of the 
production process, GcMAF was checked for sterility in-
house and externally by independent laboratories. Its 
safety and biological activity were tested in monocytes, 
human breast  cancer  cells  and chick  embryo 
chorionallantoic  membrane (Pacini et al., 2011; 
Pacini et al., 2012; Thyer et al., 2013c). Highly 
purified OA (molecular weight, 282.46; molecular 
formula, C18 H34 O2; Acros Organics, Geel, 
Belgium) was complexed with GcMAF in accordance 
with the molecular structure described in Thyer et al. 
(2013c). The optimal conditions for the preparation of 
the complexes were established according to the 
principles described in Knyazeva et al. (2008). 
Because of the complexing of the protein with the 
fatty acid hydrophobic moiety together with the well-
known properties of OA as an absorption enhancer, 
OA-GcMAF complexes could also be administered 
sublingually (Cui et al., 2005; Sakata et al., 2011), as 
an aerosol with a common nebuliser (Lu et al., 2011), 
or as suppositories (Goto et al., 1991). 
2.2. Assessment of OA-GcMAF Induced 
Immunotherapeutic Effects 
Macrophage activation in vivo could be assessed by 
monitoring the patient’s blood pressure before and after 
OA-GcMAF administration. Thus, it is well known that 
activated macrophages release nitric oxide a compound 
that causes vasodilatation and seems to be responsible 
for some of the anti-cancer properties of activated 
macrophages (Stuehr and Nathan, 1989; Nathan and 
Hibbs, 1991; Hiroi et al., 2013). It has been consistently 
observed that a small but significant decrease in both 
systolic and diastolic blood pressure, e.g. from 137/84 to 
122/71. In our experience, the administration of OA-
GcMAF (880 ng dissolved in 5 mL saline) with a 
nebuliser resulted in the most rapid decrease of blood 
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pressure with the effects clearly appreciable 1 min after 
the end of the nebulisation. In order to have another 
assessment of immune stimulation, the splenic blood 
flow has been monitored with an ultrasound system 
(MyLab25Gold, Esaote, Genoa, Italy) using the echo-
colour-doppler technique.  An  increase in the peripheral 
splenic blood flow has been consistently observed after 
OA-GcMAF administration and it persisted for several 
days (Fig. 1A and 1B). 
2.3. Integrative Cancer Immunotherapy with 
OA-GcMAF  
The standard protocol of our integrative cancer 
immunotherapy is as follows: 
OA-GcMAF (880 ng) has been administered daily 
using the route of administration that was regarded as 
most suitable for each patient e.g., in patients with lung 
cancer or metastases, the preference was to administer 
OA-GcMAF with a nebuliser. In patients with liver cancer 
or metastases, the preference was through suppositories. In 
other cases, the intramuscular route as originally proposed 
by Yamamoto et al. (2008a) was the preferred route. 
2.4. Other Complementary Integrative 
Approaches 
In order to exploit the synergistic anti-cancer 
properties of vitamin D3 and bearing in mind that GcMAF 
constitutes part of the vitamin D axis (Thyer et al., 2013c), 
patients have taken a nutritional supplementation of 
vitamin D3 at 20,000 IU per day (Den Hollander et al., 
2013) with monitoring the blood levels of such a vitamin. 
Patients are taught to drink at least 2 litres of water (or 
other liquids such as herbal teas) per day. 
Patients have followed a nutritional regime based 
on the recent scientific observations demonstrating 
that a very low carbohydrate, high protein diet slows 
tumor growth and prevents cancer initiation (Ho et al., 
2011). In order to favour the compliance to this type 
of diet, non-glucidic food containing only 2% of 
carbohydrates and a relatively high protein content 
(Le Gamberi Foods, Forlì, Italy) have been provided. 
The patients’ weight and muscle mass is monitored 
and they are taught the strategies to decrease the 
Prognostic Inflammatory Nutritional Index (PINI) score 
is upheld as well as strategies to avoid Cancer Anorexia 
Cachexia Syndrome (CACS) according to Fabris et al. 
(2012). The supplementation with amino acids (Master 
Aminoacid Patter, International Nutrition Research 
Center, Coral Gables, FL, USA) is also intended for this 
scope (Lucà-Moretti et al., 2003). 
In order to exploit the well-known immune 
stimulating and anticancer effects of probiotic fermented 
milk products (Lakritz et al., 2013), a probiotic 
fermented milk product containing colostrum and 
microorganisms that are known to produce a natural 
GcMAF from the Gc-globulin in the milk and colostrum 
during the fermentation process (Bravo Probiotic, Les 
Alpes, Wellington, NZ) has also been administered.   
 
 
 
Fig. 1. Increased splenic blood flow following administration of OA-GcMAF. Oleic Acid (OA) complexed with vitamin D binding 
protein-derived Macrophage Activating Factor (OA-GcMAF, Goleic; Immuno Biotech Ltd, Guernsey, Channel Islands), 880 
ng, dissolved in 5 mL saline, was administered by nebulisation. Splenic blood flow was assessed by echo-colour-doppler 
ultrasonographic technique. Panel A, basal, i.e., before any administration of OA-GcMAF. Panel B, 48 h after OA-GcMAF 
administration. The increase in peripheral splenic blood flow is evident. This picture is representative of several others that 
gave qualitatively identical results 
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Finally, considering the well assessed role of low-
dose acetylsalicylic acid in cancer prevention    
(Thorat and Cuzick, 2013), patients have been 
receiving a 100 mg dose per day. 
3. RESULTS 
At the end of October 2013, patients with cancer started 
treatment at the Immuno Biotech Treatment Centre using 
the OA-GcMAF integrative approach described above. By 
the end of February 2014, immuno biotech had treated 30 
patients. When the primary tumor or the metastasis could be 
accurately measured by ultrasonographic techniques, it has 
been observed, on average, a decrease of tumor volume of 
approximately 25% in a week. Although this reduction may 
appear dramatic, it is fully consistent with the results 
reported by Nonaka et al. (2012), who observed a 97% 
volume reduction of human hepatocellular carcinoma after 
3 weeks of subcutaneous injection with GcMAF. It is also 
consistent with the results reported for neoadjuvant 
chemotherapy (Partridge et al., 2005). 
Among the patients observed at the Immuno Biotech 
Treatment Centre, we present several cases here each as 
a representative of common cancers for whom this 
integrative immunotherapy was remarkably effective. To 
our knowledge, this is the first example of actual images 
of tumor volume reduction following GcMAF 
immunotherapy. In effect, so far the effectiveness of 
immunotherapy of cancer with GcMAF has relied upon 
non-specific markers such as serum α-N-
acetylgalactosaminidase levels (Yamamoto et al., 2008a; 
2008b; 2008c; Thyer et al., 2013a) or anecdotic reports 
(Inui et al., 2013; Thyer et al., 2013b). 
Patient 1 
A 63-year-old woman was diagnosed with colon cancer 
in 1997. A CT scan performed in April 2013 had confirmed 
metastases in lung and liver. The scan of the liver reported a 
distortion of the superior liver suspected due to pleural 
carcinomatosis (diaphragmatic invasion probable) and 
invasion of the liver surface also possible. After 2 weeks of 
integrative immunotherapy where OA-GcMAF was 
administered by alternating nebulisation and intramuscular 
injections, the lesion at the level of the liver, measured with 
ultrasonography showed a decrease of calculated volume 
from 13 to 6.6 mL (Fig. 2A and 2B). 
Patient 2 
A 62-year-old woman was diagnosed with multiple 
myeloma. After 4 weeks of integrative immunotherapy 
where OA-GcMAF was administered by intramuscular 
injections, the monocytes almost doubled (from 
0.39×109/L to 0.70×109/L). This finding is consistent with 
the original observation that GcMAF stimulates the bone 
marrow production of the progenitor cells for extensive 
mitogenesis and activation of macrophages, thus 
rebuilding the immune system (Yamamoto and 
Naraparaju, 1998). The stimulation of the immune system 
in this case could also be determined by the increase of 
lymphocytes that were abnormally low before the 
integrative immunotherapy (0.81×109/L) and had returned 
to normal level in afterward (1.59×109/L). Also the total 
number of white blood cells returned to normal level 
(5.0×109/L) from previously low levels (3.3×109/L). Also 
the modest increase of platelets (from 187 to 201×109/L) 
and of red blood cells (from 3.31 to 3.48×1012/L) has to be 
interpreted as a consequence of successful macrophage 
activation. Thus, that it has been known for a long time 
that nitric oxide released by activated macrophages 
stimulates bone marrow haematopoiesis (Iversen et al., 
1994; Cokić and Schechter, 2008). In addition to multiple 
myeloma and independently of this condition, this patient 
had simple breast cysts that could be visualised by 
ultrasonography. It has been determined that a significant 
decrease in the major diameter of one of these cysts, that 
was taken as being representative of the others. The 
diameter decreased from 5.4 to 3.8 mm (Fig. 3A and B). 
It is well assessed that breast cysts, although non-
malignant, develop when an overgrowth of glands and 
connective tissue block milk ducts, causing them to dilate 
and fill with fluid (Guinebretière et al., 2005). Therefore, 
the observed effects of the integrative immunotherapy on 
the size of this breast cyst seem to indicate that this 
approach could be effective in controlling abnormal cell 
growth even when this is not frankly malignant. 
Patient 3 
A 43-year-old woman was diagnosed with metastatic 
breast cancer to bone and liver in February 2013. After 1 
week of integrative immunotherapy where OA-GcMAF 
was administered by localised subcutaneous injections, the 
primary tumor at the level of the breast, measured with 
ultrasonography showed a decrease of calculated volume 
from 1.8 to 1.3 mL (Fig. 4A and B). This case was 
representative of four other cases of breast cancer that 
qualitatively gave similar results. 
Patient 4 
A 60-year-old man was diagnosed with metastatic 
thyroid cancer to bone and soft tissue. After 4 weeks of 
integrative immunotherapy where OA-GcMAF was 
administered by alternating nebulisation and localised 
subcutaneous injections, one of the bone metastases 
taken as representative, measured with ultrasonography 
showed a decrease of its thickness from 43.3 to 37.3 mm 
(Fig. 5A and B). 
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Fig. 2. Ultrasonography of liver metastasis. A 63-year-old woman was diagnosed with colon cancer in 1997. A CT scan performed 
in April 2013 had confirmed metastases in lung and liver. After 2 weeks of integrative immunotherapy where OA-GcMAF 
(880 ng/day) was administered by alternating nebulisation and intramuscular injections, the lesion at the level of the liver 
showed a decrease of calculated volume from 13 ml (panel A) to 6.6 mL (panel B). This corresponds to approximately a 50% 
overall reduction 
 
 
 
Fig. 3. Ultrasonography of breast cyst.A 62-year-old woman was diagnosed with multiple myeloma. After 4 weeks of integrative 
immunotherapy where OA-GcMAF (880 ng/day) was administered by intramuscular injections, the diameter of one benign breast 
cysts decreased from 5.4 mm (panel A) to 3.8 mm (panel B). This corresponds to approximately a 65% overall reduction 
 
 
 
Fig. 4. Ultrasonography of breast cancer. A 43-year-old woman was diagnosed with metastatic breast cancer to bone and liver in 
February 2013. After 1 week of integrative immunotherapy where OA-GcMAF  (880 ng/day) was administered by localised 
subcutaneous injections, the primary tumour at the level of the breast, measured with ultrasonography, showed a decrease of 
calculated volume from 1.8 mL (panel A) to 1.3 mL (panel B). This corresponds to approximately a 28% overall reduction. 
This case was representative of four other cases of breast cancer that qualitatively gave similar results 
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Patient 5 
A 78-year-old man was diagnosed with metastatic 
renal carcinoma. After 2 weeks of integrative 
immunotherapy where OA-GcMAF was administered by 
alternating nebulisation and intramuscular injections, one 
of the kidney lesions taken as representative, measured 
with ultrasonography, showed a decrease of its diameter 
from 33.7 to 29.8 mm (Fig. 6A and B). 
Patient 6 
A 36-year-old man was diagnosed with metastatic 
melanoma. After 1 week of integrative immunotherapy 
where OA-GcMAF was administered by alternating 
nebulisation and intramuscular injections, one of the 
lesions in the abdomen, interpreted as coalescent 
metastatic peritoneal nodes, measured with 
ultrasonography, showed a decrease of its length from 
52.1 to 48.6 mm (Fig. 7A and B). 
Patient 7 
A 55-year-old woman was diagnosed with metastatic 
adenocarcinoma of the colon. After 3 weeks of integrative 
immunotherapy where OA-GcMAF was administered by 
alternating nebulisation, intramuscular injections and 
suppositories, one of the lesions in the abdomen, 
interpreted as one of the metastases previously described, 
measured with ultrasonography, showed a decrease of its 
length from 76.8 to 70.1 mm (Fig. 8A and B). 
 
 
 
Fig. 5. Ultrasonography of bone metastasis. A 60-year-old man was diagnosed with metastatic thyroid cancer to bone and soft tissue. 
After 4 weeks of integrative immunotherapy where OA-GcMAF (880 ng/day) was administered by alternating nebulisation 
and localised subcutaneous injections, one of the bone metastases taken as representative, measured with ultrasonography, 
showed a decrease of its thickness from 43.3 mm (panel A) to 37.3 mm (panel B). This corresponds to an approximate 14% 
linear diameter reduction. In this case the volume could not be fully extrapolated since the mass showed an irregular shape 
 
 
 
Fig. 6. Ultrasonography of kidney metastasis. A 78-year-old man was diagnosed with metastatic renal carcinoma.  After 2 weeks of 
integrative immunotherapy where OA-GcMAF (880 ng/day) was administered by alternating nebulisation and intramuscular 
injections, one of the kidney lesions taken as representative, measured with ultrasonography, showed a decrease of its 
diameter from 33.7 mm (panel A) to 29.8 mm (panel B). This corresponds to approximate a 31% overall reduction 
Emma Ward et al. / American Journal of Immunology 10 (1): 23-32, 2014 
 
29 Science Publications
 
AJI 
 
 
Fig. 7. Ultrasonography of abdominal nodes. A 36-year-old man was diagnosed with metastatic melanoma.  After 1 week of 
integrative immunotherapy where OA-GcMAF (880 ng/day) was administered by alternating nebulisation and intramuscular 
injections, one of the lesions in the abdomen, interpreted as coalescent metastatic peritoneal nodes, measured with 
ultrasonography, showed a decrease of its length from 52.1 mm (panel A) to 48.6 mm (panel B). This corresponds to an 
approximate 7% linear diameter reduction. In this case the volume could not be fully extrapolated since the mass showed an 
irregular elongated shape 
 
 
 
Fig. 8. Ultrasonography of abdominal metastasis. A 55-year-old woman was diagnosed with metastatic adenocarcinoma of the 
colon.  After 3 weeks of integrative immunotherapy where OA-GcMAF (880 ng/day) was administered by alternating 
nebulisation, intramuscular injections and suppositories, one of the lesions in the abdomen, interpreted as one of the 
metastases previously described, measured with ultrasonography, showed a decrease of its length from 76.8 mm (panel A) 
to 70.1 mm (panel B). This corresponds to an approximate 9% linear diameter reduction. In this case the volume could not 
be fully extrapolated since the mass showed an irregular elongated shape 
 
4. DISCUSSION 
OA-protein complexes are bound to play a leading 
role in cancer therapy (Smith, 2013) thanks to the 
selectivity of antitumoral effects, absence of side effects, 
safety and oral availability (Artym and Zimecki, 2013; 
Puthia et al., 2014). 
The synthesis of OA-GcMAF, combines the known 
anticancer effects of OA-protein complexes with the 
anticancer and immune stimulating effects of GcMAF. In 
fact, it is well assessed that GcMAF, in addition to 
activating tumoricidal macrophages (Thyer et al., 2013c), 
directly inhibits cancer cell proliferation (Gregory et al., 
2010; Pacini et al., 2012) as well as cancer cell-induced 
neo-angiogenesis. 
On account of the natural absorption enhancing 
activity of OA, the complexed OA-GcMAF represents the 
physiological assembly of naturally occurring GcMAF. 
This new formulation allows GcMAF to be administered 
through a variety of more desirable routes that eliminate a 
major obstacles to its widespread use. This feature favours 
a treatment tailored to the individual patient’s 
characteristics, with the possibility of delivering the OA-
GcMAF to the sites where it can best exert its action. 
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Table 1. Showing the decrease in tumour volumes (as calculated by ultrasonography measurements), with the types of cancer treated 
and the no of weeks treatment at the point of measurement 
  Weeks treated for (%) Measured 
Patient Cancer presentation observed results decrease 
1 Metastatic colon cancer 2 49.2 
2 Multiple myeloma 4 29.6 
3 Metastatic breast cancer 1 27.7 
4 Metastatic thyroid cancer 4 13.9 
5 Metastatic renal carcinoma 2 11.6 
6 Metastatic melanoma 1 6.8 
7 Metastatic adenocarcinoma of colon 3 8.7 
 
We are well aware that the clinical cases reported 
here are heterogeneous and describe patients with 
different types of tumors at different stages. In all cases, 
patients had undergone a variety of conventional and 
complementary. In all cases, integrative immunotherapy 
was initiated at late stages of tumor progression since it 
is understandable that conventional therapies were 
preferred at earlier stages. In addition, since this is an 
open-label, non-controlled, retrospective analysis, 
caution must be employed when ascribing cause and 
effect to any treatment outcome. However, the response 
to integrative immunotherapy was robust (Table 1) and, 
even though any statistical analysis is inappropriate in 
such an heterogeneous recollection of clinical stories, the 
absence of adverse side effects and clinical improvement 
supported by objective evidences emerge evident. 
5. CONCLUSION 
To our knowledge, the ultrasonographic images 
shown here represent the first direct evidence 
demonstrating an anticancer effect of GcMAF (OA-
GcMAF in this case) in humans. They show a significant 
reduction in tumor size (Table 1) and are fully consistent 
with the actual images of tumor shrinkage shown by 
Nonaka et al. (2012) reporting on the effects of GcMAF 
in human hepatocarcinoma cells transplanted in SCID-
mice. They also show a consistent increase in splenic 
blood flow that has to be interpreted in the context of 
generalised immune system activation and allows to 
assess almost immediately the degree of 
responsiveness of the individual patient. Therefore, 
we suggest that diagnostic imaging rather than 
measurement of α-N-acetylgalactosaminidase should 
become the gold standard to assess the efficacy of 
GcMAF treatment in cancer patients.  
Although almost all patients were late stage 4, it was 
a requirement that they were well enough to travel and 
be active enough to cope with residency at the Treatment 
Centre. All of these patients have showed significant 
clinical improvements. These patients will be followed 
up and reported on more fully at a later date. 
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